Quantcast

Latest Clinical trial Stories

2014-09-16 08:30:30

"PIM" Designation For DCVax-L Is First Step In 2-Step Process for Early Access Approval BETHESDA, Md., Sept. 16, 2014 /PRNewswire/ -- Northwest Biotherapeutics (NASDAQ: NWBO) ("NW Bio"), a biotechnology company developing DCVax® personalized immune therapies for solid tumor cancers, announced today that its DCVax-L is the first product to receive formal designation as a "Promising Innovative Medicine" (PIM) under the new "Early Access to Medicines Scheme" (EAMS) launched in the UK...

2014-09-15 12:24:42

TUCSON, Ariz., Sept. 15, 2014 /PRNewswire-USNewswire/ -- "Best practices" in medicine are based on clinical trials, which are supposedly at the highest level of evidence. But instead of bringing sound science into drug testing, clinical trials have brought a neglect of patients' individual needs and an epidemic of over-prescribing, writes Henry Bauer, Ph.D., in the fall issue of the Journal of American Physicians and Surgeons. The benefits of vaccination or antibiotics are readily...

2014-09-15 08:29:58

PLYMOUTH MEETING, Pa., Sept. 15, 2014 /PRNewswire/ -- Inovio Pharmaceuticals, Inc. (NASDAQ: INO) announced today that it has met the stringent listing criteria for the NASDAQ Global Select Market and effective today has transferred to this U.S. stock exchange from the NYSE MKT. The company will continue to trade under its current ticker symbol, "INO." NASDAQ Global Select Market, a segment of the NASDAQ Global Market, maintains the highest initial listing standards of any exchange...

2014-09-15 08:29:32

- Significantly Improved Agitation in 220-Patient 10-week Study - ALISO VIEJO, Calif., Sept. 15, 2014 /PRNewswire/ -- Avanir Pharmaceuticals, Inc. (NASDAQ: AVNR) today announced positive results from its phase II clinical trial evaluating the safety and efficacy of AVP-923 for the treatment of agitation in patients with Alzheimer's disease. Treatment with AVP-923 was associated with significantly reduced agitation as measured by the primary endpoint, the agitation/aggression...

2014-09-15 08:29:28

Company CEO to present on September 17, 2014 JERUSALEM, September 15, 2014 /PRNewswire/ -- Oramed Pharmaceuticals Inc. (NASDAQCM: ORMP) (http://www.oramed.com), a clinical-stage pharmaceutical company focused on the development of oral drug delivery systems, announced today the Company's CEO, Nadav Kidron will present at DC Finance's Family Office & Wealth Management Annual Conference. Presentation Details: DC Finance's East Coast Family Office & Wealth...

2014-09-15 08:29:14

BETHESDA, Md., Sept. 15, 2014 /PRNewswire/ -- Northwest Biotherapeutics (NASDAQ: NWBO) ("NW Bio"), a U.S. biotechnology company developing DCVax® personalized immune therapies for solid tumor cancers, announced today that Linda F. Powers, CEO, will present at SMi's 3rd Annual Cancer Vaccines Conference being held in Central London on September 15-16, 2014. http://photos.prnewswire.com/prnvar/20110329/SF73084LOGO Ms. Powers' presentation will provide updates about the Company's...

2014-09-15 04:21:20

AARHUS, Denmark, September 15, 2014 /PRNewswire/ -- The success rate of assisted reproduction was significantly increased by the use of revolutionary time-lapse technology A study accepted for publication in the renowned scientific journal Fertility & Sterility [http://www.fertstert.org/article/S0015-0282(14)01365-X/abstract ], confirms that a revolutionary and clinically certified technology can substantially increase the success rate in assisted reproduction....

2014-09-12 23:04:25

Medrio brings new Phase I EDC software focus to SCDM San Francisco, CA (PRWEB) September 12, 2014 Medrio, a provider of eClinical Software as a Service (SaaS) and Cloud EDC™ for clinical research, will exhibit at SCDM 2014. After great success at this year’s BIO and DIA conferences, Medrio is excited to showcase its new product suite with an expanded presence at the 20th annual SCDM conference. “SCDM is our third major industry conference in six months, and we are thrilled with...

2014-09-11 23:11:35

Three companies—one European, two American—have teamed up to enable European manufacturers of implantable ophthalmic devices to comply with anticipated regulatory demands for ongoing post-market outcomes data. ZURICH, MADISON, WI, and NEW YORK (PRWEB) September 11, 2014 Three companies—one European, two American—have teamed up to enable European manufacturers of implantable ophthalmic devices to comply with anticipated regulatory demands for ongoing post-market outcomes data. In...

2014-09-11 23:02:43

A research team from the Icahn School of Medicine at Mount Sinai today received a $12 million grant from the National Institutes of Health to create a center that will screen massive data sets for new uses of existing drugs, and confirm them in human cell tests. New York, NY (PRWEB) September 11, 2014 A research team from the Icahn School of Medicine at Mount Sinai today received a $12 million grant from the National Institutes of Health to create a center that will screen massive data...


Word of the Day
reremouse
  • A bat.
The word 'reremouse' comes from Middle English reremous, from Old English hrēremūs, hrērmūs ("bat"), equivalent to rear (“to move, shake, stir”) +‎ mouse.
Related